[//]:content-type-MARKDOWN-DONOT-DELETE Gate Research's latest report, "Deconstructing the Real-World Challenges and Paradigm Shift of the 'Innovative Drugs' Narrative Under the DeSci Framework," provides an in-depth analysis of the rise of decentralized science (DeSci) in the biopharmaceutical sector, its current development status, and its structural mismatch with traditional innovative drug R&D models. This study explores the real-world challenges DeSci faces in life sciences and examines its future development path. ![](https://gimg2.staticimgs.com/image/article/1739776332emile_en.webp) ### Key Takeaways: **Crypto Narrative Enters Life Sciences:** Since Q4 2024, DeSci has become a focal point in the crypto industry, with KOLs like Vitalik showing support. DeSci-related topics on Platform X now exceed 500,000 daily impressions. By leveraging blockchain, DeSci aims to address issues like opaque research funding allocation, journal monopolies, and data-sharing challenges, fostering a more transparent and open research ecosystem. **Innovative Drugs vs. DeSci:** DeSci primarily focuses on the biopharmaceutical sector, while high-end disciplines like materials science, information science, and nuclear physics have yet to establish effective ecosystems. Most DeSci tokens with a market cap exceeding $30 million are linked to biopharma, reflecting the crypto industry’s capital shift toward life sciences after fulfilling basic demands. **Challenges in Biopharma:** Innovative drug development relies on centralized institutions for clinical trials, whereas DeSci lacks the mature infrastructure to support large-scale testing. The crypto industry favors high-efficiency returns, but drug R&D cycles span 10-15 years, making aligning with crypto's capital operations difficult. **Potential Breakthroughs for DeSci:** Decentralized research funds like VitaDAO are exploring on-chain funding distribution to enhance transparency and support early-stage research. The tokenization of research data via NFTs could facilitate data sharing and IP transactions, lowering barriers to innovative drug development. Additionally, by adopting the Real World Asset (RWA) tokenization model, DeSci can introduce on-chain financing solutions to expand funding sources for biopharma. **Click here to download PDF 👉🏻 Gate Research: Deconstructing the Real-World Challenges and Paradigm Shift of the "Innovative Drugs" Narrative Under the DeSci Framework ** **Gate Research** Gate Research is a comprehensive blockchain and cryptocurrency research platform that provides readers with in-depth content, including technical analysis, key insights, market reviews, industry research, trend forecasts, and macroeconomic policy analysis. Click the link to visit now. *Disclaimer This content does not constitute any offer, solicitation, or financial advice. We strongly recommend consulting with a qualified financial advisor before making investment decisions. Users should be aware that Gate services may be restricted in certain regions. For complete terms and conditions, please refer to our User Agreement at https://www.gate.io/user-agreement. Please note that cryptocurrency investments carry high risks. Before investing, it's essential to thoroughly research and understand the assets and products you're interested in. Gate bears no responsibility for any losses or damages resulting from your investment choices. * **Gateway to Crypto** Trade over 3,600 cryptocurrencies safely, quickly, and easily on Gate • Visit our Official Website • Download Gate App / Web now • Follow us on Gate X (Twitter) to get more bonuses • Join our Telegram to discuss hot topics • Join our Global Community to get more updates • We provide 100% proof of reserve • Sign up to enjoy max. $10,000 in rewards exclusively for new users • Get 40% commission from referrals Gate Team February 17, 2025